Published in Medicine and Law Weekly, September 23rd, 2005
The collaboration gives Ciphergen exclusive rights to license discoveries made during the agreement and is part of the University's ongoing research in ovarian cancer.
"This agreement allows us to expand our current research in oncology by working with Doctor van Nagell and his colleagues," said Gail Page, president and chief operating officer of Ciphergen. "The University of Kentucky is a major referral center for the treatment of gynecologic malignancies. We are very pleased to be collaborating in our mutual goal to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly